![]() More, rather than less, opioid daily dosages could be prescribed to certain individual patients who have high impact, intractable pain,” said an anonymous poster.īut the DEA said it would proceed as planned and take a wait-and-see approach to the revised guideline before making any changes to its aggregate production quotas (APQ). “I believe that the DEA must take into consideration these revised Guidelines, because physicians will no longer be constrained to any arbitrary, hard and fast limit. Several people also pointed out that the CDC recently updated its opioid guideline to emphasize there is no hard limit on doses and to give doctors more flexibility in prescribing opioids. It's quite clear that access to prescription opioids is a problem, so I'm not at all sure what you think you'll gain from reducing production - you're just going to kill people,” wrote Amber Bullington. Why in the world are you reducing AGAIN?! Stop torturing Americans with your disastrous policies. There already is a large shortage of pain meds. The government has to get out of healthcare and respect patient privacy again.” ![]() “The DEA are acting as doctors and determining how a doctor does his or her job. All the street drugs out there come from Mexico by way of China, NOT a pharmacy,” wrote Anne Hoch. There is no correlation between prescriptions and diversion. “The DEA should not impose further reduction in the supply of Rx opioids for 2023. Many fear that further cuts in the opioid supply will lead to more suffering and suicides due to untreated pain. Over 350 people and organizations commented on the DEA’s new quotas during a 30-day public comment period that ended in mid-November. Prescription opioid use has fallen by nearly 50 percent in recent years, but drug deaths have climbed to record levels, fueled primarily by street drugs made with illicit fentanyl. ![]() It’s hard to find any evidence that reducing the opioid supply prevents overdoses. Since their peak in 2013, DEA production quotas have fallen by 65% for oxycodone and 73% for hydrocodone. The 5% production cut in 2023 for Schedule II opioids is not as steep as in prior years, but continues a trend that began a decade ago. In a notice published in the Federal Register, DEA said the reduced supply of opioids in 2023 would be “sufficient to meet all legitimate needs.” The agency has broad legal authority under the Controlled Substances Act (CSA) to establish annual production quotas for drug manufacturers, based on estimated medical, scientific and research needs. ![]() Drug Enforcement Administration has finalized plans to further reduce the supply of oxycodone, hydrocodone and other commonly prescribed opioids by about 5 percent in 2023, ignoring complaints from patients and healthcare providers that a seventh consecutive year of cuts in opioid production would cause shortages and interfere with the treatment of pain patients. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |